An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * New Study Shows that Ozempic® Reduces the Risk of Heart Attack, Stroke, and Death by 23% Compared to Dulaglutide On September 18, Novo Nordisk announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was […]
Pharma Fridays – September 19, 2025
Join the Global Movement Advancing Endocrine Science and Medicine
Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.